PureTech Health PLC PDMR Notification RSU Vesting
28 February 2025 - 4:30AM
RNS Regulatory News
RNS Number : 7607Y
PureTech Health PLC
27 February 2025
27
February 2025
PureTech Health
plc
PDMR
Notifications
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to giving life to
new classes of medicine to change the lives of patients with
devastating diseases, announces that
awards of restricted share units ("RSUs") granted by PureTech on 18 May
2022 to certain directors and other persons discharging managerial
responsibilities ("PDMRs")
pursuant to its Performance Share Plan ("PSP") vested on 24 February 2025
following satisfaction of performance conditions
measured over the three year period to 31 December
2024.
Each PDMR received vested ordinary
shares (after deduction of shares for payroll taxes) on 26 February
2025. The market price per ordinary share
in the Company used to calculate the amount payable to the PDMRs
and the amount of shares to be issued to PDMRs was 144.6 pence,
being the average closing price of the Company's shares over the
three-trading day period immediately preceding the vesting date,
and the exchange rate used to calculate the cash payment and amount
of share settlement was £1: $1.26.
The Company's total issued ordinary
share capital is 257,927,489 shares after the share issuance to the
PDMRs, 17,738,040 shares of which are held in treasury by the
Company.
PDMR Notification
The information contained in the below notification is
disclosed in accordance with Article 19 of the EU Market Abuse
Regulation.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Bharatt Chowrira
Eric Elenko
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Bharatt Chowrira - Chief Executive
Officer
Eric Elenko - President
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
PureTech Health plc
|
|
b)
|
LEI
|
213800LVPDNO2Z9T9I39
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
|
Ordinary Shares of PureTech Health plc
ISIN GB00BY2Z0H74
|
|
|
|
b)
|
Nature of the transaction
|
Issuance of ordinary shares in net settlement of certain
vested RSUs under the PureTech Health Performance Share Plan, after
retentions in respect of payroll taxes.
|
|
c)
|
Price(s) and volume(s)
|
|
Recipient
|
Price
|
Amount
|
|
Bharatt Chowrira
|
0.01
GBP
|
108,103
ordinary shares
|
|
Eric Elenko
|
0.01
GBP
|
118,710
ordinary shares
|
|
|
d)
|
Aggregated information
|
|
Price
|
Aggregate
Volume
|
|
0.01 GBP
|
226,813 ordinary shares
|
|
|
e)
|
Date of the transaction
|
26 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
About PureTech
Health
PureTech is a clinical-stage biotherapeutics
company dedicated to giving life to new classes of medicine to
change the lives of patients with devastating diseases. The Company
has created a broad and deep pipeline through its experienced
research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced
both internally and through its Founded Entities. PureTech's
R&D engine has resulted in the development of 29 therapeutics
and therapeutic candidates, including three that have been approved
by the U.S. Food and Drug Administration. A number of these
programs are being advanced by PureTech or its Founded Entities in
various indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points.
For more information, visit
www.puretechhealth.com
or connect with us on X (formerly Twitter)
@puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHPPUBGPUPAGCM
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Feb 2025 to Mar 2025
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Mar 2024 to Mar 2025
